

DAFTAR PUSTAKA

- Al Olayan, A., Al Hussaini, H., dan Rahman Jazieh, A., 2012. The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer. *Journal of Infection and Public Health*, **5**: S50–S60.
- American Pharmacists Association, 2011. Drug Information Handbook.
- Annunziata, M.C., Ferrillo, M., Cinelli, E., Panariello, L., Rocco, D., dan Fabbrocini, G., 2019. Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: Our Experience in Lung Cancer. *Open Access Macedonian Journal of Medical Sciences*, **7**: 973–977.
- Chan, J.C., Lee, Y.H., Liu, C.Y., Shih, H.H., Tsay, P.K., dan Tang, W.R., 2019. A Correlational Study of Skin Toxicity and Quality of Life in Patients with Advanced Lung Cancer Receiving Targeted Therapy. *Journal of Nursing Research*, **27**: 1–9.
- Charles, C., Bungener, C., Razavi, D., Mateus, C., Routier, E., Lanoy, E., dkk., 2016. Critical Reviews in Oncology / Hematology Impact of dermatologic adverse events induced by targeted therapies on quality of life. *Critical Reviews in Oncology / Hematology*, **101**: 158–168.
- Chen, J.Y., Liang, S.K., Chuang, T.Y., Chu, C.Y., Tu, C.H., Yeh, Y.J., dkk., 2023. The impact of comorbidities, neutrophil-to-lymphocyte ratio, and drug toxicities on quality of life in lung cancer patients receiving EGFR-TKI therapy. *Journal of the Formosan Medical Association*, .
- Chen, L., Brown, J., Marmaduke, D.Q., Mayo, C., Grau, G., Lau, Y.K., dkk., 2018. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan® research database. *Supportive Care in Cancer*, **26**: 2369–2377.
- Chen, S.C., 2012. Health-Related Quality of Life in Dermatology: Introduction and Overview. *Dermatologic Clinics*, **30**: 205–208.
- Chen, Y., Wen, S., Wu, Y., Shi, L., Xu, X., dan Shen, B., 2021. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-

mutant non-small cell lung cancer: A syste. *Critical Reviews in Oncology/Hematology*, **163**: 103393.

Clinicalkey, 2022, Lung Cancer (Non–Small Cell, stage IV) 1–45.

Colombino, M., Paliogiannis, P., Cossu, A., Santeufemia, D.A., Lung, S., Slc, C., dkk., 2019. alterations in 1440 Sardinian patients with lung adenocarcinoma 1–10.

Dewanti, H.R., 2018. Profil Dan Angka Tahan Hidup 1 Tahun Kanker Paru Bukan Sel Kecil (KPKBSK) Jenis Adenokarsinoma Paru Dengan Mutasi Epidermal Growth Factor Receptor (EGFR) Exon 20 T790M Primer Di RSUP.

Dsouza, P.C. dan Kumar, S., 2017. Role of systemic antibiotics in preventing epidermal growth factor receptor: Tyrosine kinase inhibitors-induced skin toxicities. *Asia-Pacific Journal of Oncology Nursing*, **4**: 323–329.

Dutta, P.R. dan Maity, A., 2007. Cellular responses to EGFR inhibitors and their relevance to cancer therapy **254**: 165–177.

Finlay, A.Y. dan Khan, G.K., 1994. Dermatology Life Quality Index (DLQI)- a simple practical measure for routine clinical use. *Clinical and Experimental Dermatology*, **19**: 210–216.

Giuliani, J. dan Bonetti, A., 2016. The Pharmacological Costs for the Management of Skin Toxicity in Patients With Cancer Treated With Epidermal Growth Factor Receptor-Inhibitors. *Clinical Lung Cancer*, **17**: 471–473.

Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W.E.E., dkk., 2016. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*, **11**: 39–51.

Gridelli, C., De Marinis, F., Di Maio, M., Cortinovis, D., Cappuzzo, F., dan Mok, T., 2011. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. *Lung Cancer*, **71**: 249–257.

- Joshi, S.S., Ortiz, S., Witherspoon, J.N., Rademaker, A., dan West, D.P., 2010. Effects of Epidermal Growth Factor Receptor Inhibitor-Induced Dermatologic Toxicities on Quality of Life 3916–3923.
- Kemenkes RI, 2017. Pedoman Nasional Pelayanan Kedokteran Kanker Paru.
- Kemenkes RI, 2020. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/ 6485/2021 Tentang Formularium Nasional **5**: 248–53.
- Khaddour, K., Jonna, S., dan Deneka, A., 2021. Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies 1–24.
- Lacouture, M.E., Sibaud, V., Gerber, P.A., Hurk, C. Van Den, Santini, D., Jahn, F., dkk., 2021. Prevention and management of dermatological toxicities related to anticancer agents : ESMO Clinical Practice Guidelines **5**. *Annals of Oncology*, **32**: 157–170.
- Laitupa, A., 2022. Efficacy of Gefitinib and Erlotinib in Non-Small-Cell Lung Carcinoma.
- Laratmase, A.J., 2016. Pengembangan Alat Ukur Kualitas Hidup Nelayan. *Jurnal Ilmiah Pendidikan Lingkungan dan Pembangunan*, **17**: 34–41.
- Macdonald, J.B., Macdonald, B., Golitz, L.E., LoRusso, P., dan Sekulic, A., 2015. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. *Journal of the American Academy of Dermatology*, **72**: 203–218.
- Maier, J., Kandelbauer, A., Erlacher, A., Cavaco-Paulo, A., dan Gübitz, G.M., 2004. A New Alkali-Thermostable Azoreductase from *Bacillus* sp. Strain SF. *Applied and Environmental Microbiology*, **70**: 837–844.
- Masago, K., Imamichi, F., Masuda, Y., Ariga, N., Fujitomi, K., Fukumine, Y., dkk., 2018. Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. *Asia-Pacific Journal of Oncology Nursing*, **5**: 430–434.
- Nan, X., Xie, C., Yu, X., dan Liu, J., 2017. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer **8**: 75712–75726.

National Cancer Institute, NCI, *Common Terminology Criteria Adverse Events*, CTCAE v.5.0 27 November 2017

NCCN, 2023. Practice Guideline: Non-Small Cell Lung.

Neo, A.G., Pérez, A., López, C., Castedo, L., dan Tojo, G., 2009. *Photocyclization of Tosylstilbenes as a Key Reaction in the Preparation of an Analogue of the Antitumor Agent CC-1065*, *Journal of Organic Chemistry*.

Passaro, A., Di Maio, M., Del Signore, E., Gori, B., dan De Marinis, F., 2014. Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: A comparison analysis. *Clinical Lung Cancer*, **15**: 307–312.

Paz-Ares, L., Tan, E.-H., O'Byrne, K., Zhang, L., Hirsh, V., Boyer, M., dkk., 2017. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. *Annals of Oncology*, **28**: 270–277.

Plużański, A. dan Piórek, A., 2016. Side Effects of Tyrosine Kinase Inhibitors: Management Guidelines **12**: 113–18.

Rahmatina, 2013. Uji validitas dan reliabilitas Dermatology Life Quality Index (DLQI) berbahasa indonesia pada pasien di Poliklinik Ilmu Kesehatan Kulit Dan Kelamin Rumah Sakit Dr Cipto Mangunkusumo = Validity and reliability test of indonesian version of Dermatology Life. *Perpustakaan Universitas indonesia*, 945.

RSUD Dr. Soetomo, 2013. Profil Penderita Kanker Paru Karsinoma Bukan Sel Kecil (KPKBSK) di RSUD Dr. Soetomo 30–34.

Salim, O.C., Sudharma, N.I., Kusumaratna, R.K., dan Hidayat, A., 2007. Validitas dan reliabilitas World Health Organization Quality of Life - BREF untuk mengukur kualitas hidup lanjut usia **26**: 27–38.

Szepietowska, M., Dąbrowska, A., Nowak, B., Skinderowicz, K., Wilczyński, B., Krajewski, P.K., dkk., 2022. Prevalence and quality of life of facial acne: a cross-sectional study in high school students in Poland. *Postepy Dermatologii i Alergologii*, **39**: 1035–1039.

Tseng, L.C., Chen, K.H., Wang, C.L., dan Weng, L.C., 2020. Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related

quality of life in patients with lung cancer: An observational study. *Medicine (United States)*, **99**: .

UpToDate, W.K., 2023a. 'Antineoplastic Agent and Tyrosine Kinase Inhibitor', 1–12.

UpToDate, W.K., 2023b. 'Erlotinib: Drug Information', 1–20.

UpToDate, W.K., 2023c. 'Afatinib: Drug Information', 1–14.

Weinstein, I.B. dan Joe, A.K., 2006. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. *Nature Clinical Practice Oncology*, **3**: 448–457.

Yamamoto, H., Toyooka, S., dan Mitsudomi, T., 2009. Lung Cancer Impact of EGFR mutation analysis in non-small cell lung cancer **63**: 315–321.

Zhang, Z., Zhang, X., Gao, Y., Chen, Y., Qin, L., dan Xy, I., 2022. Risk Factors for the Development of Lung Cancer among Never Smoker: A Systematic Review **81**: 87.

Zhao, Y., Cheng, B., Chen, Zisheng, Li, J., Liang, H., Chen, Y., dkk., 2021. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. *Critical Reviews in Oncology/Hematology*, **160**: .